Cullinan Therapeutics, Inc. - 8-K Filing
Cullinan Therapeutics announced initial Phase 1 trial results for CLN-978 in treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). As of January 14, 2026, data showed robust B cell depletion (>75% reduction from baseline levels), with promising clinical activity including DAS28-ESR improvements in RA patients and SLEDAI score reductions. The company will present updated findings at the EULAR Congress in June. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $CGEM